Evidence map›Paper›PMID 28819887›Full record

ArticleJournal of cancer research and clinical oncology2017

Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?

A Radtke, J-F Cremers, S Kliesch, S Riek, K Junker, S A Mohamed, P Anheuser, G Belge, K-P Dieckmann

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

A RadtkeFaculty of Biology and Chemistry, University of Bremen, Leobener Str. 2, 28359, Bremen, Germany. aradtke@uni-bremen.de.ORCID http://orcid.org/0000-0002-2439-9699
J-F CremersDepartment of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, University of Muenster, Muenster, Germany.
S KlieschDepartment of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, University of Muenster, Muenster, Germany.
S RiekFaculty of Biology and Chemistry, University of Bremen, Leobener Str. 2, 28359, Bremen, Germany.
K JunkerDepartment of Pathology, Klinikum Bremen-Mitte, Bremen, Germany.
S A MohamedDepartment of Cardiac and Thoracic Vascular Surgery, University of Luebeck, Luebeck, Germany.
P AnheuserDepartment of Urology, Albertinen Krankenhaus, Hamburg, Germany.
G BelgeFaculty of Biology and Chemistry, University of Bremen, Leobener Str. 2, 28359, Bremen, Germany.
K-P DieckmannDepartment of Urology, Albertinen Krankenhaus, Hamburg, Germany.
University of Bremen · DEKlinikum Bremen-Mitte · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDiagnosing germ cell neoplasia in situ (GCNis) can detect germ cell tumours (GCTs) at the pre-invasive stage. To date, testicular biopsy with the potential of surgical complications is the only way of safely diagnosing GCNis. Recently, microRNAs (miRs) 371-3, and miR 367 were shown to be valuable serum biomarkers of GCTs. We explored the usefulness of these candidate miRs as a marker for GCNis.

methods27 patients with GCNis and no concomitant GCT were enrolled. All patients underwent measuring serum levels of miR-371a-3p and miR-367-3p before treatment, 11 had repeat measurement after treatment, 2 also had testicular vein blood examinations. Serum levels were measured by quantitative PCR. In addition, four orchiectomy specimens of patients with GCT were examined immunohistochemically and by in situ hybridization (ISH) with a probe specific for miR-371a-3p to look for the presence of this miR in GCNis cells.

resultsThe median serum level of miR-371a-3p was significantly higher in patients with GCNis than in controls, miR-367 levels were not elevated. Overall, 14 patients (51.9%) had elevated serum levels of miR-371a-3p. The highest levels were found in patients with bilateral GCNis. Levels in testicular vein serum were elevated in both of the cases. After treatment, all elevated levels dropped to normal. In two orchiectomy specimens, miR-371a-3p was detected by ISH in GCNis cells.

conclusionsMeasuring miR-371a-3p serum levels can replace control biopsies after treatment of GCNis. In addition, the test can guide clinical decision making regarding the need of testicular biopsy in cases suspicious of GCNis.

Indexed as

AdolescentAdultBiomarkers, TumorCarcinoma in SituCase-Control StudiesFollow-Up StudiesHumansMaleMicroRNAsMiddle AgedNeoplasm InvasivenessNeoplasms, Germ Cell and EmbryonalNeoplasm StagingPrognosisSurvival RateTesticular NeoplasmsBiomarkers, TumorMicroRNAsMIRN371 microRNA, humanGerm cell neoplasia in situGerm cell tumourmicroRNAQuantitative polymerase chain reactionTesticular biopsy

Identifiers

PMID28819887
PMCPMC5640733
OpenAlexW2748420241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.